Evaluation of patients with phenylalanine metabolism disorder: a single center experience
Author:
Erdol Sahin1ORCID, Bilgin Huseyin1ORCID
Affiliation:
1. Department of Pediatrics , Division of Metabolism, Uludag University Faculty of Medicine , Bursa , Turkey
Abstract
Abstract
Aim
The aim is to evaluate the clinical, demographic and laboratory data of the patients we followed up with phenylalanine metabolism disorder.
Materials and methods
In this study, patients with phenylalanine metabolism disorder who applied to Bursa Uludag University Faculty of Medicine, Department of Pediatrics, Pediatric Metabolism Department between 2011 and 2021 were retrospectively examined. The files of 397 patients who were followed up in our pediatric metabolism outpatient clinic and were found to have phenylalanine metabolism disorder by plasma phenylalanine level and molecular genetic analysis were evaluated.
Results
According to the highest plasma phenylalanine levels at admission, mild hyperphenylalaninemia phenotype constituted the largest group of 397 patients with 282 cases (71.1%), while the least common phenotype was malignant phenylketonuria (BH4 metabolism disorder) with four patients (1.0%). The number of patients with classical phenylketonuria was 90 (22.6%). 61 (62.8%) of 97 phenylalanine metabolism disorder cases who underwent BH4 loading test had a response. The mean phenylalanine level of the patients was 3.62 ± 1.31 mg/dL in mild hyperphenylalaninemia, 7.98 ± 3.99 mg/dL in mild phenylketonuria and 11.71 ± 4.39 mg/dL in classical phenylketonuria. While 241 (76%) of 317 patients younger than 8 years old were in the well-controlled group, 76 (24%) were in the poorly-controlled group. While 41 (53.9%) of 76 patients older than 8 years of age were in the well-controlled group, 35 (46.1%) were in the poorly-controlled group.
Conclusions
In our study, the largest patient group consisted of patients with mild hyperphenylalaninemia, and the least common phenotype was mild phenylketonuria.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference22 articles.
1. Flydal, MI, Martinez, A. Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life 2013;65:341–9. https://doi.org/10.1002/iub.1150. 2. Shi, XT, Cai, J, Wang, YY, Tu, WJ, Wang, WP, Gong, LM, et al.. Newborn screening for inborn errors of metabolism in mainland China: 30 years of experience. JIMD Rep 2012;6:79–83. https://doi.org/10.1007/8904_2011_119. 3. Chen, T, Xu, W, Wu, D, Han, J, Zhu, L, Tong, F, et al.. Mutational and phenotypic spectrum of phenylalanine hydroxylase deficiency in Zhejiang Province, China. Sci Rep 2018;8:17137. https://doi.org/10.1038/s41598-018-35373-9. 4. Ozalp, I, Coşkun, T, Tokatli, A, Kalkanoğlu, HS, Dursun, A, Tokol, S, et al.. Newborn PKU screening in Turkey: at present and organization for future. Turk J Pediatr 2001;43:97–101. 5. Tezel, B, Dilli, D, Bolat, H, Sahman, H, Ozbaş, S, Acıcan, D, et al.. The development and organization of newborn screening programs in Turkey. J Clin Lab Anal 2014;28:63–9. https://doi.org/10.1002/jcla.21645.
|
|